Congenital anomalies: Treatment options based on amniotic fluid-derived stem cells

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Over the past decade, amniotic fluid-derived stem cells have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. There are a number of unique properties of amniotic fluid stem cells that have allowed it to become a major research focus. These include the relative ease of accessing amniotic fluid cells in a minimally invasive fashion by amniocentesis as well as the relatively rich population of progenitor cells obtained from a small aliquot of fluid. Mesenchymal stem cells, c-kit positive stem cells, as well as induced pluripotent stem cells have all been derived from human amniotic fluid in recent years. This article gives a pediatric surgeon's perspective on amniotic fluid stem cell therapy for the management of congenital anomalies. The current status in the use of amniotic fluid-derived stem cells, particularly as they relate as substrates in tissue engineering-based applications, is described in various animal models. A roadmap for further study and eventual clinical application is also proposed.

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
Issue number3
StatePublished - Jul 2012
Externally publishedYes


  • Amniotic fluid
  • Congenital anomalies
  • Fetal therapy
  • Fetus
  • Mesenchymal stem cells
  • Stem cell therapy
  • Stem cells
  • Tissue engineering

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology
  • Developmental Biology
  • Transplantation


Dive into the research topics of 'Congenital anomalies: Treatment options based on amniotic fluid-derived stem cells'. Together they form a unique fingerprint.

Cite this